Acerus Pharmaceuticals Co. (TSE:ASP) Director Stephen Robert Gregory bought 320,000 shares of the firm’s stock in a transaction dated Friday, December 7th. The shares were acquired at an average price of C$0.14 per share, for a total transaction of C$44,800.00.
Stephen Robert Gregory also recently made the following trade(s):
- On Monday, September 10th, Stephen Robert Gregory bought 94,000 shares of Acerus Pharmaceuticals stock. The shares were acquired at an average price of C$0.24 per share, for a total transaction of C$22,560.00.
Shares of ASP stock traded up C$0.01 during trading hours on Friday, hitting C$0.14. 358,600 shares of the company’s stock were exchanged, compared to its average volume of 201,706. The company has a debt-to-equity ratio of 105.08, a quick ratio of 0.29 and a current ratio of 0.69. Acerus Pharmaceuticals Co. has a 52 week low of C$0.12 and a 52 week high of C$0.42.
ILLEGAL ACTIVITY WARNING: “Acerus Pharmaceuticals Co. (ASP) Director Stephen Robert Gregory Acquires 320,000 Shares of Stock” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://transcriptdaily.com/2018/12/08/acerus-pharmaceuticals-co-asp-director-stephen-robert-gregory-acquires-320000-shares-of-stock.html.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.
Featured Article: What is the quiet period?
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.